The Hemodynamics of Hypertension -- The Importance of Pathophysiology and Pharmacology CME

Author Information and Disclosures

Release Date: May 13, 2008; Valid for credit through May 13, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

© Copyright 2008 American Society of Hypertension, Inc.
Forest Pharmaceuticals
Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Review the basics of the hemodynamics of hypertension and understand how hemodynamics may form the platform for phenotypic expression.
  2. Recognize the various mechanisms for control of vascular tone.
  3. Utilize hemodynamic concepts in the selection of pharmacologic agents, including new vasodilating beta-blockers, for the treatment of cardiovascular disease.
Authors and Disclosures

Thomas D. Giles, MD
Disclosure: Thomas D. Giles, MD, has disclosed that he has received grants-in-aid from AstraZeneca and Novartis AG, and that he is a consultant for Boehringer Ingelheim Corporation, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Forest Laboratories, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and sanofi-aventis. Dr. Giles has also disclosed that he has served as an advisor for Daiichi Sankyo Co., Ltd., Forest Laboratories, Inc., and Novartis AG.


Joseph L. Izzo, Jr., MD
Disclosure: Joseph L. Izzo, Jr., MD, has disclosed that he has received grants-in-aid from GlaxoSmithKline and Novartis AG, and that he is a consultant for Boehringer Ingelheim, Daiichi-Sankyo, Forest Laboratories, Merck, Novartis, and Takeda. Dr. Izzo has also disclosed an association with Medcepts, LLC.


David Good
Disclosure: David Good has disclosed no relevant financial relationships.
 
American Society of Hypertension
The American Society of Hypertension is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASH designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.